Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-08-28
2004-11-02
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S027000, C514S034000, C514S283000, C514S449000, C536S123100
Reexamination Certificate
active
06812220
ABSTRACT:
BACKGROUND
A surgical adhesion is a type of scar that forms between two parts of the body, usually after surgery. Adhesions can cause severe problems. For example, adhesions involving the female reproductive organs (ovaries, Fallopian tubes) can cause infertility, dyspareunia (painful intercourse) and severe pelvic pain. Adhesions that occur in the bowel can cause bowel obstruction or blockage, and adhesions can also form in other places such as around the heart, spine and in the hand. In addition to surgery, adhesions can be caused by things such as endometriosis, infection, chemotherapy, radiation and cancer.
Adhesions, as well as other angiogenic related diseases such as arthritis and psoriasis, can last for weeks, months or years, requiring extended and costly care. See
Robbins Pathological Basis of Disease
by Cotran, R. S., Kumar, V., Robbins, S. L., p75 (W. B. Saunders Co., 1989). Such diseases and conditions can develop into chronic inflammatory conditions with terrible consequences to both the mental and physical well-being of the patient. Unfortunately, there are few therapeutic options for patients with surgical adhesions, arthritis, and psoriasis. Often patients are treated with drugs such as steroidal or non-steroidal anti-inflammatories to relieve the symptoms of the diseases. However, these therapies may not offer adequate long-term benefit and are associated with serious side effects if used too frequently (such as gastric ulcers from non-steroidal anti-inflammatories or more serious toxicities from overuse of steroids). Other, more potent, anti-proliferative and/or anti-angiogenic drugs such as the anticancer drugs paclitaxel, methotrexate, doxorubicin, camptothecin and etoposide might offer aggressive treatment modalities but use of these drugs against non-life threatening diseases are limited by unwanted toxicities and side effects.
Thus, there has gone unmet a need for compounds, compositions, methods and the like (including delivery approaches) to treat one or more of these diseases, preferably more effectively with few side effects. The present compounds, compositions, methods, etc., provide one or more of these advantages.
SUMMARY
Compositions and methods comprising fucans, and particularly fucoidan, for the treatment of surgical adhesions, arthritis, and psoriasis. The fucans provide significant therapeutic effect for each of these diseases while also providing low side effects.
In one aspect, the present invention provides methods of treating an adhesion in an animal, which can be a human or other desired subject, comprising administering a therapeutically effective amount of a fucan, which can be fucoidan to a disease site potentially having an adhesion. The disease site can be a surgical site, and the fucan can be directly delivered as a composition to the disease site. The fucan can be substantially continuously administered to the disease site via controlled release from a polymeric dosage form, and the polymeric dosage form can be a film, patch, paste, microsphere, implant, gel, spray or liquid. The fucan can be administered as a pharmaceutical composition in a form comprising at least one of a cream, paste, injectable excipient and polymer. (Unless expressly stated otherwise or clear from the context, all embodiments, aspects, features, etc., can be mixed and matched, combined and permuted in any desired manner.)
The fucan can be administered as a pharmaceutical composition comprising the fucan and a therapeutically effective amount of at least one other drug. The drug can be at least one of a paclitaxel, doxorubicin, camptothecin, etoposide, mitoxantrone, methotrexate, menadione, plumbagin, juglone, beta-laperchone cyclosporin, sulfasalazine, steroid, rapamycin, retinoid, docetaxel, and colchicine, antisense oligonucleotide, ribozyme. The therapeutically effective amount of the fucan can be delivered as a part of a composition and the fucan can be from about 0.1% to 35%, 5% to 50%, 20-80%, 80% to 100% w/v of the composition.
The composition further can comprise at least one pharmaceutically acceptable excipient, such as a pluronic, cellulose, alginate, acrylate, hyaluronic acid, polyethylene glycol, injectable excipient, and chitosan. The fucan can be administered orally, directly to the disease site, via injection to the disease site, intraocularly, intraperitoneally, intramuscularly, intraarticularly, intralesionally, subcutaneously, intravaginally, rectally or topically, or otherwise as desired.
In another aspect, the methods comprise treating arthritis, psoriasis or angiogenic eye diseases, comprising administering a therapeutically effective amount of the fucan to a disease site.
In further aspects, the present invention provides pharmaceutical compositions comprising a polymeric dosage form of the fucan comprising a therapeutically effective amount of the fucan and at least one pharmaceutically acceptable excipient selected from the group consisting of a pluronic, alginate, acrylate, hyaluronic acid, polyethylene glycol, injectable excipient, and chitosan. The polymeric dosage form can be a film, paste, microsphere, spray, lotion, liquid, or implant or other form as desired. The pharmaceutical compositions can also comprise a therapeutically effective amount of at least one other drug such as an antisense oligonucleotide, ribozyme and an oligonucleotide RNA inhibitor.
The compositions can be used in the manufacture of a medicament for treating an adhesion, such as a surgical adhesion, arthritis, psoriasis or other diseases as desired. Also provided are methods of manufacturing a medicament able to reduce symptoms associated with at least one of an adhesion, arthritis, and psoriasis in a human patient, comprising combining a pharmaceutically effective amount of a fucan such as fucoidan, a pharmaceutically acceptable excipient or buffer.
These and other aspects, features and embodiments are set forth within this application, including the following Detailed Description and attached drawings. In addition, various references are set forth herein, including in the Cross-Reference To Related Applications, that discuss certain systems, apparatus, methods and other information; all such references are incorporated herein by reference in their entirety and for all their teachings and disclosures, regardless of where the references may appear in this application.
REFERENCES:
patent: 3971848 (1976-07-01), Kasahara et al.
patent: 5705177 (1998-01-01), Roufa et al.
patent: 6020326 (2000-02-01), Roufa et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 0 293 826 (1988-12-01), None
patent: 0 645 143 (1995-03-01), None
patent: 01-031707 (1989-02-01), None
patent: 64-085905 (1989-03-01), None
patent: 01-313433 (1989-12-01), None
patent: WO 92/19761 (1992-11-01), None
patent: WO 01/82936 (2001-11-01), None
Patrick Chauvet et al “Inhibition of Platelet-Neutrophil Interactions by Fucoidan Reduces Adhesion and Vasorestriction After Acute Arterial Injury By Angioplasty in Pigs” Journal of Cardiovascular Pharmacology, 1999, 34, 597-603.*
Robert Langer “New Methods of Drug Delivery”, Science, 1990, 24, 1527-1532.*
Jen-Her Lu et al, J. Thorac. Cardiovasc. Surg. 1998, 115(5), 1111-20.*
PCT International Search Report, PCT/CA02/01337, Dec. 20, 2002.
Bittuon, Patrick, et al., Low-Molecular-Weight Dextran Derivatives (f-CMDB) Enter The Nucleus And Are Better Cell-Growth Inhibitors Compared With Parent CMDB Polymers, Carbohydrate Research, vol. 322, pp. 247-255 (1999).
Blondin, Catherine, et al., Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) From Brown Seaweed, Molecular Immunology, vol. 31, No. 4, pp. 247-253 (1994).
Brandley, Brian K., et al., Multiple Carbohydrate Receptors on Lymphocytes Revealed by Adhesion to Immobilized Polysaccharides, J. Cell Biology, vol. 105, pp. 991-997 (1987).
Giraux, Jean-Luc, et al., Modulation of Human Endothelial Cell Proliferation and Migration by Fucoidan and Heparin, European J. Cell Biology, vol. 77, pp. 352-359 (1998).
Glabe, Charles G., et al., Reversible Disruption of Cultured Endot
Burt Helen M.
Jackson John K.
Graybeal Jackson Haley LLP
Krishnan Ganapathy
University of British Columbia
Wilson James O.
LandOfFree
Pharmaceutical compositions and methods relating to fucans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods relating to fucans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods relating to fucans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3315409